Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.52 |
| ▸ | AR | P10275 | 4/20 | 0.49 |
| ▸ | BTK | Q06187 | 2/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23051560 | 0.92 | CRBN (0.53) | CRBNARBTKDDB1ESR1 | |
| SCHEMBL24031726 | 0.89 | CRBN (0.54) | CRBNARBTKDDB1ESR1 | |
| SCHEMBL29597268 | 0.89 | CRBN (0.62) | CRBNARBTKDDB1ESR1 | |
| SCHEMBL26808203 | 0.87 | CRBN (0.54) | CRBNARBTKDDB1ESR1 | |
| SCHEMBL23051639 | 0.87 | CRBN (0.49) | CRBNARBTKDDB1ESR1 | |
| SCHEMBL26808846 | 0.87 | CRBN (0.54) | CRBNARBTKDDB1ESR1 | |
| SCHEMBL24031618 | 0.86 | CRBN (0.49) | CRBNARBTKDDB1ESR1 | |
| SCHEMBL24031399 | 0.86 | CRBN (0.54) | CRBNARBTKDDB1ESR1 | |
| SCHEMBL24031847 | 0.86 | CRBN (0.54) | CRBNARBTKDDB1ESR1 | |
| SCHEMBL24031374 | 0.85 | CRBN (0.59) | CRBNARBTKDDB1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388978-A1 | CEREBLON E3 LIGASE INHIBITORS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-08 | — | — | US | disclosed |
| CN-114641337-A | CEREBLON E3 ligase inhibitors | 密歇根大学董事会 | 2022-06-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388978-A1 | CEREBLON E3 LIGASE INHIBITORS | CRBN, CUL3, UBE3A | CRBN 1/4885AR 1383/4885BTK 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.